We are live on
!
Find out more
First Trust Advisors Portfolio holdings
AUM
$140B
1-Year Est. Return
27.84%
This Fund
S&P 500
This Quarter
Est. Return
+1.3%
1 Year Est. Return
+27.84%
3 Year Est. Return
+78.79%
5 Year Est. Return
+98.89%
10 Year Est. Return
+456.9%
AUM
$38.5B
AUM Growth
+$4.48B
(+13%)
Cap. Flow
+$4.55B
Cap. Flow
% of AUM
11.82%
Top 10 Holdings %
Top 10 Hldgs %
13.89%
Holding
2,364
New
149
Increased
1,180
Reduced
895
Closed
134
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Trust NYSE Arca Biotechnology Index Fund
FBT
|
+$275M |
| 2 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$221M |
| 3 |
First Trust Dow Jones Internet Index Fund ETF
FDN
|
+$193M |
| 4 |
First Trust Consumer Staples AlphaDEX Fund
FXG
|
+$188M |
| 5 |
First Trust Consumer Discretionary AlphaDEX Fund
FXD
|
+$179M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$230M |
| 2 |
Spectrum Brands
SPB
|
+$81.6M |
| 3 |
Chevron
CVX
|
+$79.8M |
| 4 |
Pfizer
PFE
|
+$66.7M |
| 5 |
K
Kellanova
K
|
+$63.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.09% |
| 2 | Consumer Discretionary | 10.38% |
| 3 | Technology | 9.81% |
| 4 | Consumer Staples | 7.93% |
| 5 | Communication Services | 6.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.81B
| $1B | 2.6% |
8,075,591
+2,278,536
| +39% | +$275M |
|
|
2
First Trust Health Care AlphaDEX Fund
FXH
$1.01B
| $798M | 2.07% |
11,588,726
+3,269,724
| +39% | +$221M |
|
|
3
First Trust Dow Jones Internet Index Fund ETF
FDN
$4.84B
| $684M | 1.77% |
10,171,646
+2,869,945
| +39% | +$193M |
|
|
4
First Trust Consumer Staples AlphaDEX Fund
FXG
$229M
| $656M | 1.7% |
14,898,059
+4,203,421
| +39% | +$188M |
|
|
5
First Trust Consumer Discretionary AlphaDEX Fund
FXD
$259M
| $627M | 1.63% |
17,170,120
+4,844,512
| +39% | +$179M |
|
6
Meta Platforms (Facebook)
META
$1.54T
| $424M | 1.1% |
4,948,881
+615,951
| +14% | +$50.3M |
|
7
Amazon
AMZN
$2.51T
| $348M | 0.9% |
16,039,320
+2,657,660
| +20% | +$55.5M |
|
8
Alphabet (Google) Class C
GOOG
$3.89T
| $335M | 0.87% |
12,627,580
+2,053,609
| +19% | +$55M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.4B
| $239M | 0.62% |
1,748,045
-24,051
| -1% | -$2.98M |
|
10
Regeneron Pharmaceuticals
REGN
$68.3B
| $238M | 0.62% |
465,690
+1,993
| +0.4% | +$973K |
|
11
Incyte
INCY
$23.3B
| $231M | 0.6% |
2,212,105
-77,519
| -3% | -$8.02M |
|
12
First Trust Exchange-Traded Fund IV First Trust Tactical High Yield ETF
HYLS
$1.61B
| $218M | 0.57% |
4,356,718
+240,685
| +6% | +$12.2M |
|
13
United Therapeutics
UTHR
$26.4B
| $216M | 0.56% |
1,239,957
+313,637
| +34% | +$56.4M |
|
14
IQVIA
IQV
$34.6B
| $212M | 0.55% |
2,916,230
+494,486
| +20% | +$33.9M |
|
15
Gilead Sciences
GILD
$162B
| $207M | 0.54% |
1,771,890
+280,049
| +19% | +$30.6M |
|
16
Biogen
BIIB
$29.6B
| $205M | 0.53% |
508,733
+166,858
| +49% | +$67M |
|
|
CELG
17
DELISTED
Celgene Corp
CELG
| $205M | 0.53% |
1,770,877
+220,679
| +14% | +$25.2M |
|
18
Charles River Laboratories
CRL
$11B
| $198M | 0.51% |
2,816,177
+679,514
| +32% | +$50.3M |
|
19
eBay
EBAY
$48.5B
| $192M | 0.5% |
7,580,775
+903,217
| +14% | +$22.5M |
|
|
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
| $191M | 0.5% |
3,339,972
+688,254
| +26% | +$42.4M |
|
21
First Trust United Kingdom AlphaDEX Fund
FKU
$37.4M
| $189M | 0.49% |
4,357,214
+3,619,120
| +490% | +$158M |
|
22
Netflix
NFLX
$287B
| $187M | 0.49% |
19,942,370
+82,600
| +0.4% | +$691K |
|
23
Alnylam Pharmaceuticals
ALNY
$35.9B
| $186M | 0.48% |
1,555,824
+301,299
| +24% | +$36M |
|
24
Illumina
ILMN
$29.8B
| $185M | 0.48% |
873,173
+45,791
| +6% | +$8.94M |
|
25
First Trust Germany AlphaDEX Fund
FGM
$95.7M
| $178M | 0.46% |
4,710,437
+3,912,480
| +490% | +$153M |
|
Similar funds
DAM
First Trust Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, First Trust Advisors held 2,364 positions worth $38.5B, up 13% from $34B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
First Trust Advisors deployed $4.55B of net new capital in Q2 2015, opening 149 new positions and adding to 1,180 existing holdings. Its largest new stake was Agios Pharmaceuticals: 1,079,286 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Chevron, an estimated $79.8M trimmed.
- First Trust Advisors's largest Q2 2015 buy was Agios Pharmaceuticals: 1,079,286 shares worth $120M.
- First Trust Advisors added most to First Trust NYSE Arca Biotechnology Index Fund in Q2 2015, an estimated $275M increase.
- First Trust Advisors's biggest Q2 2015 reduction was Chevron, cutting an estimated $79.8M.
- First Trust Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $230M.
- First Trust Advisors's ten largest holdings make up 14% of its $38.5B portfolio in Q2 2015.
- First Trust Advisors opened 149 new positions and closed 134 in Q2 2015.
- First Trust Advisors's portfolio value rose 13% quarter-over-quarter to $38.5B.
Based on First Trust Advisors's 13F filing for Q2 2015, filed 4 Aug 2015.